FRI0197 NNC0109-0012 (anti-IL-20 MAB), well tolerated in patients with rheumatoid arthritis

P. Leszczyński; M.K. Eshof; H.V.B. Stegmann; N.P. Hundahl Møller; L.B. Graff

doi:10.1136/annrheumdis-2012-eular.2654

Article info

Scientific Abstracts

Poster Presentations

Posters

Rheumatoid arthritis – other biologic treatment

FRI0197 NNC0109-0012 (anti-IL-20 MAB), well tolerated in patients with rheumatoid arthritis

Authors

P. Leszczyński 1Department of Rheumatology and Rehabilitation, University of Medical Sciences, Poznan, Poland PubMed articles Google scholar articles
M.K. Eshof 2Clinical Operation Inflammation PubMed articles Google scholar articles
H.V.B. Stegmann 3BioStat Pharm PubMed articles Google scholar articles
N.P. Hundahl Møller 4Inflammation PubMed articles Google scholar articles
L.B. Graff 5Medical and Science, Inflammation, Novo Nordisk A/S, Søborg, Denmark PubMed articles Google scholar articles

Citation

Leszczyński P, Eshof M, Stegmann H, et al

FRI0197 NNC0109-0012 (anti-IL-20 MAB), well tolerated in patients with rheumatoid arthritis

Annals of the Rheumatic Diseases 2013;71:379-380.

Publication history

First published January 23, 2014.

Online issue publication

March 05, 2018

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password